CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM
October 07, 2022 08:00 ET
|
CNS Pharmaceuticals, Inc.
LOS ANGELES, Oct. 07, 2022 (GLOBE NEWSWIRE) -- InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for...